QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: jpet.106.114447v1 320/3/1195    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Oitate, M. Articles by Ikeda, T. Search for Related Content PubMed PubMed Citation Articles by Oitate, M. Articles by Ikeda, T.

CARDIOVASCULAR

Mechanism for Covalent Binding of Rofecoxib to Elastin of Rat Aorta

Drug Metabolism and Pharmacokinetics Research Laboratories (M.O., M.T., T.M., S.M, T.I.), Core Technology Research Laboratories (T.Ho.), R&D Headquarters (T.O.), and R&D Project Management Department (T.Hi.), Sankyo Co., Ltd., Tokyo, Japan; and Department of Nursing, Kiryu Junior College, Gunma, Japan (A.S.)

We have previously reported that oral administration of [¹⁴C]rofecoxib to rats resulted in the long retention of radioactivity by the aorta as a consequence of covalent binding to elastin. Treatment of rats with -phenyl--propylbenzeneacetic acid 2-[diethylamino]-ethyl ester hydrochloride (SKF-525A), a cytochrome P450 inhibitor, significantly decreased the systemic exposure of 5-hydroxyrofecoxib, one of the main metabolites of rofecoxib, whereas there was no statistically significant change in the retention of radioactivity from [¹⁴C]rofecoxib in the aorta. On the other hand, the aortic retention of radioactivity closely correlated to the systemic exposure of unchanged rofecoxib in the dose range between 2 and 10 mg/kg. A covalent binding study of [¹⁴C]rofecoxib in vitro using rat aorta homogenate in the presence of D-penicillamine, hydralazine, -aminopropionitrile, and sodium borohydride suggested that the aldehyde group of allysine in elastin was relevant to the covalent binding. In a model reaction using benzaldehyde, rofecoxib but not 5-hydroxyrofecoxib reacted with the aldehyde group of benzaldehyde in a manner of condensation reaction under a physiological pH condition. A histopathological examination using an electron microscope demonstrated that multiple oral administration of rofecoxib to rats caused marked degradation of the elastic fiber system of the aorta. These results suggested that rofecoxib as such is reactive in vivo, undergoing a condensation reaction with allysine, thereby preventing the formation of cross-linkages in elastin, i.e., desmosine and isodesmosine, and causing the degradation of the elastic fibers.

Address correspondence to: Masataka Oitate, Drug Metabolism and Pharmacokinetics Research Laboratories, Sankyo Co., Ltd., 1-2-58, Hiromachi, Shinagawa-ku, Tokyo 140-8710, Japan. E-mail: masataka{at}sankyo.co.jp

This article has been cited by other articles:

				M. Oitate, T. Hirota, T. Murai, S.-i. Miura, and T. Ikeda Covalent Binding of Rofecoxib, but Not Other Cyclooxygenase-2 Inhibitors, to Allysine Aldehyde in Elastin of Human Aorta Drug Metab. Dispos., October 1, 2007; 35(10): 1846 - 1852. [Abstract] [Full Text] [PDF]